U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393334) titled 'Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive' on Dec. 31, 2025.
Brief Summary: NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be randomized in a crossover design to receive a single dose of NLS-133, an active control or placebo either 90 or 180 minutes prior to collection of semen. Sperm parameters measured will be count, motility and morphology. A brief questio...